Author

M. Amjad

h-index 0 View on Semantic Scholar

We have 3 of 8 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Efficacy and safety of carboplatin-containing chemotherapy in triple-negative breast cancer: A comprehensive systematic review, meta-analysis, and trial sequential analysis with BRCA/HRD subgroup assessment.

BackgroundTriple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options. Platinum agents, particularly carboplatin's DNA damaging properties suggest efficacy, its impact on survival outcomes and toxicity remains uncertain.MethodsPubMed, Embase, Scopus, Cochrane Library, and Clini...

M. Amjad, M. Bashir, Khwaja Waleed Maqbool et al. · Journal of Oncology Pharmacy... · 0 citations

Review Sep 2026

Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer: A Systematic Review, Meta-Analysis, and GRADE Assessment of Randomized Evidence.

OBJECTIVES Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to eva...

M. Amjad, Maryam Rafique, Syeda F. Hussain et al. · American Journal of Clinical... · 0 citations

Review Jul 2026

Can baxdrostat redefine blood pressure control in resistant and uncontrolled hypertension? a systematic review, meta-analysis, and trial sequential analysis.

Baxdrostat, particularly at 2 mg, provides clinically meaningful BP reductions, and serious safety outcomes remain entirely comparable to control, which highlights a reassuring safety profile.

B. Khan, Muhammad Yahya, H. Khan et al. · Naunyn-Schmiedeberg's Archiv... · 1 citation